ATHE News and Press, Alterity Therapeutics Limited From 04/15/24

2024-04-15 12:47:11 ET More on Mid-day movers & stocks. Enlivex stock plunges 50% on mixed results from sepsis study WiSA Technologies to effect 1-for-150 reverse stock split Seeking Alpha’s Quant Rating on BioSig Technologies, Inc. Historical earn...

2024-04-15 08:21:07 ET More on Pre-market losers & stocks. OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript Monogram Orthopaedics, Inc. (MGRM) Q4 2023 Earnings Call Transcript Monogram Orthopaedics, Inc. 2023 Q4 - Results - Earnings Call Presentation ...

2024-04-11 08:16:21 ET More on pre-market losers stock Grifols: Q4 Was Positive, Still Too Many Question Marks Altice USA: Recent Refinancing Buys Time But Challenges Remain Altice USA, Inc. (ATUS) Q4 2023 Earnings Call Transcript Altice slips as Wells Fargo ...

MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today a...

2024-03-26 11:11:56 ET More on Alterity Therapeutics Alterity Therapeutics drops on capital raise Seeking Alpha’s Quant Rating on Alterity Therapeutics Historical earnings data for Alterity Therapeutics Financial information for Alterity Therapeutics ...

MELBOURNE, Australia and SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative...

2024-02-23 13:39:42 ET More on Alterity Therapeutics Alterity jumps after promising data on Parkinson's candidate Seeking Alpha’s Quant Rating on Alterity Therapeutics Historical earnings data for Alterity Therapeutics Financial information for Alterit...

2024-02-23 10:00:17 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming UBS concedes it wasn't bullis...

– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – – Baseline Biomarker Data to be Presented from Ongoing ATH434-201 Phase 2 Clinical Trial – MELBOURNE, Australia and SAN FR...

- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company&#x...